Success Stories: Our Team’s Efficient Case Preparation Strategy Gets NIW Approval for a Postdoctoral Fellow in Pharmacy from Bangladesh Without RFE
Client’s Testimonial:
“It's been a great pleasure working with you too. You people are amazing. Big congratulations to everyone related to this petition. You will be one of the contributors to my life/career here in the USA. Thanks again for always being helpful during the process.”
On November 22nd, 2021, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Pharmacy (Approval Notice).
General Field: Pharmacy
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Bangladesh
State of Residence at the Time of Filing: Virginia
Approval Notice Date: November 22nd, 2021
Processing Time: 7 months, 28 days
Case Summary:
Our NIW (National Interest Waiver) client from Bangladesh is one of the experts in the field of pharmacy. His proposed endeavor is to continue his research on developing effective aerosol formulations using in vivo studies to confirm optimal aerosol stability in order to provide improved treatments for lung disease. Since the NIW category is part of the EB2 provision which waives the labor certification requirement and offer of a permanent job in the U.S., it demands clear proof that the applicant’s research is indeed of national importance. This our team at NAILG was able to prove by using the following information:
- That his research has resulted in 26 peer-reviewed journal articles (19 of them first-authored) and 5 conference articles (3 of them first-authored).
- His original research on nationally important topics like respiratory drug delivery and formulation development has been cited 202 times.
- He has been invited to conduct reviews for international magazines some 31 times in the past showing how highly valued is his expertise in the field.
- He has pursued research directly related to his proposed endeavor of developing effective aerosol formulations using in vivo studies to confirm optimal aerosol stability in order to provide improved treatments for lung disease for 14 years.
- His proposed endeavor of developing effective aerosol formulations using in vivo studies to confirm optimal aerosol stability in order to provide improved treatments for lung disease directly addresses critical issues related to lung disease treatment in the United States and around the world.

